News and Trends 11 Jan 2023 Lifesciences and biotech in 2023 A Q&A with Bill Coyle, principal, ZS. ZS is a management consulting and technology firm focused on transforming global healthcare. In some ways, 2022 could be seen as a challenging year—at least financially—in biotech. Do you see those trends continuing? Although we see overall sentiments to invest in biotech turning positive in 2023 after a […] January 11, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 Boehringer Ingelheim and 3T Biosciences to develop next-generation cancer immunotherapies Boehringer Ingelheim and 3T Biosciences have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune […] January 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 ErVaccine raises €4.5M to start therapeutic cancer vaccine trial ErVaccine Technologies, announces the closing of a €4.5 million ($4.8 million) seed round, including dilutive and non-dilutive funds, with Seventure and Bpifrance as part of the Aide au Développement de l’Innovation (ADI) program. ErVaccine is a biotech company and spin-off from the Centre Léon Bérard-Centre de Recherche en Cancérologie de Lyon, France, which develops next-generation […] January 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 Cartherics granted first patent in China Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, has been granted a Chinese patent, “Genetically modified cells and uses thereof.” The patent provides a proprietary position for multiple development candidates in Cartherics’ pipeline. Specifically, it covers Cartherics’ chimeric antigen receptor (CAR) targeting tumor-associated glycoprotein-72 (TAG-72), along with T […] January 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 New biomarker for early prediction of response to CAR-T cell therapy A MedUni Vienna research team in Austria has discovered a new highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment. The current findings are an essential step forward towards optimizing this promising therapy. The results of the study were recently published […] January 9, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 Transgene approved for IV oncolytic virus trial Transgene has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I clinical trial of TG6050. TG6050 is a novel oncolytic virus (OV) that will be administered intravenously in patients with advanced non-small cell lung cancer (NSCLC). Transgene is […] January 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023Beyond Biotech podcast 28: Mainz Biomed, Newron Pharmaceuticals This week, we have two guests. We have conversations with Newron CEO, Stefan Weber, and Mainz Biomed CEO, Guido Bächler. Mainz Biomed year-end corporate review Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced its corporate summary for the fiscal year ended December 31, 2022. The company launched […] January 6, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 Ensoma acquiring Twelve Bio Arix Bioscience, a global venture capital company focused on investing in breakthrough biotechnology companies, announced that portfolio company Twelve Bio will be acquired by Ensoma in connection with an $85 million financing of Ensoma which Arix co-led, investing $9 million. Twelve Bio is a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas medicines. […] January 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 C2i Genomics extends AstraZeneca cancer deal C2i Genomics, a cancer intelligence company, today announced an extension of a collaboration with AstraZeneca. The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers, with the goal of enhancing oncology treatment, supporting clinical trial recruitment, and monitoring. C2i genomics has completed AstraZeneca’s BeyondBio Innovation Hub’s […] January 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 BioNTech partnering with UK Government on personalized mRNA cancer immunotherapies BioNTech SE has signed a memorandum of understanding (MoU) with the Government of the United Kingdom. The deal is set to benefit patients by speeding up clinical trials for personalized mRNA immunotherapies. The aim is to provide personalized cancer therapies for up to 10,000 patients by the end of 2030, either through clinical trials or […] January 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 5 Jan 2023 Navignostics maps tumor proteomes to improve precision oncology New cancer drugs are entering the market every year, but it’s hard to know which patients they benefit the most. The Swiss firm Navignostics is making spatial maps of the tumor’s proteome to identify the right treatment for the patient and boost precision oncology approaches. A wide range of technologies is being deployed in the […] January 5, 2023 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 Cancer Research UK and Turbine to partner on program Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK, has announced that it is partnering with Turbine AI, a tech-enabled biotech leveraging its proprietary Simulated Cell platform to solve complex diseases. The partnership will utilize Turbine AI’s platform to identify target patient populations […] January 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email